Group 1 - The stock price of the biopharmaceutical company,药捷安康-B (2617.HK), surged by 53% to reach 295 HKD, setting a new record since its IPO, with a market capitalization exceeding 110 billion HKD [1] - Since its listing on June 23, the stock price has increased over 21 times from the IPO price of 13.15 HKD within less than three months [1] Group 2 -药捷安康 is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small molecule therapies for oncology, inflammation, and cardiovascular metabolic diseases [3] - The company's core product, Tinengotinib, is a unique MTK inhibitor in the registration clinical stage, targeting the treatment of several recurrent or refractory solid tumors [3] - On September 10, 2025, the company received clinical implied approval from the National Medical Products Administration of China for its Phase II clinical trial of Tinengotinib combined with Fulvestrant for treating hormone receptor-positive (HR+) and HER2-negative or low-expressing recurrent or metastatic breast cancer [3]
药捷安康再度飙升，盘中一度涨53%报295港元再创上市新高！上市不到3个月飙升超21倍，市值升破1100亿港元
Ge Long Hui·2025-09-15 05:59